Maxalt Smelt

Rizatriptan, the active ingredient in Maxalt Smelt, is a triptan presented as an oral tablet for oral use. It is employed for the acute treatment of migraine attacks in adults and works by targeting serotonin receptors to relieve headache pain and associated symptoms when taken at the onset of an attack.

GNH USA supplies Maxalt Smelt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare providers worldwide.

Rizatriptan is a selective 5‑HT1B/1D receptor agonist used in the acute treatment of migraine.

Migraine attack: provides rapid relief of headache and associated symptoms when taken at the onset of an attack. Migraine with aura: reduces headache severity and associated neurological symptoms. Menstrual migraine: helps alleviate headache during the menstrual cycle.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Chest discomfort or tightness - Throat tightness or pressure - Nausea or vomiting - Dizziness or light‑headedness - Tingling or numbness in the extremities - Fatigue or drowsiness

Serious or Rare Side Effects: - Serotonin syndrome, especially when combined with other serotonergic agents - Coronary artery vasospasm leading to chest pain or myocardial ischemia - Severe allergic reactions such as anaphylaxis or angioedema

Before using Maxalt Smelt, consider the following safety measures.

Cardiovascular disease: assess risk and avoid use in uncontrolled coronary conditions. History of stroke or transient ischemic attack: contraindicated. Concomitant MAO‑inhibitors: avoid due to risk of serotonin syndrome. Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. Drug interactions: review all serotonergic medications and adjust therapy as needed. Store at ambient temperature: keep in the original container, protect from moisture and light.

Rizatriptan can interact with several drug classes; monitoring and avoidance are recommended where appropriate.

Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - Other triptans or ergot derivatives: additive vasoconstrictive effects. - Certain anti‑migraine agents (e.g., dihydroergotamine): heightened cardiovascular risk.

Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, or other serotonergic antidepressants: watch for signs of serotonin excess. - Antihypertensive agents: possible enhancement of blood‑pressure lowering effects. - Strong CYP3A4 inhibitors: may raise rizatriptan plasma concentrations.